1-3 of 3
Jordi Esteve
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party

Ali Bazarbachi, Myriam Labopin, Tobias Gedde-Dahl, Peter Remenyi, Edouard Forcade, Nicolaus Kröger, Gerard Socié, Charles Craddock, Jean Henri Bourhis, Jurjen Versluis, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Jean El-Cheikh, Gesine Bug, Jordi Esteve, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4441–4448.
https://doi.org/10.1158/1078-0432.CCR-23-0954
Published: 01 November 2023
View article titled, Improved Posttransplant Outcomes in Recent Years for AML Patients with <em>FLT3</em>-ITD and Wild-type <em>NPM1</em>: A Report from the EBMT Acute Leukemia Working Party
Open the PDF for Improved Posttransplant Outcomes in Recent Years for AML Patients with <em>FLT3</em>-ITD and Wild-type <em>NPM1</em>: A Report from the EBMT Acute Leukemia Working Party in another window
Journal Articles

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Eytan M. Stein, Daniel J. DeAngelo, Jörg Chromik, Manik Chatterjee, Sebastian Bauer, Chia-Chi Lin, Cristina Suarez, Filip de Vos, Neeltje Steeghs, Philippe A. Cassier, David Tai, Jean-Jacques Kiladjian, Noboru Yamamoto, Rogier Mous, Jordi Esteve, Hironobu Minami, Stephane Ferretti, Nelson Guerreiro, Christophe Meille, Rajkumar Radhakrishnan, Bernard Pereira, Luisa Mariconti, Ensar Halilovic, Claire Fabre, Cecilia Carpio
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 870–881.
https://doi.org/10.1158/1078-0432.CCR-21-1295
Published: 01 March 2022
View article titled, Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <em>TP53</em> Solid Tumors and Acute Leukemia
Open the PDF for Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <em>TP53</em> Solid Tumors and Acute Leukemia in another window
Includes: Supplementary data
Journal Articles

Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years

Ali Bazarbachi, Christoph Schmid, Myriam Labopin, Dietrich Beelen, Igor Wolfgang Blau, Victoria Potter, Riitta Niittyvuopio, Gerard Socié, Didier Blaise, Jaime Sanz, Fabio Ciceri, Iman Abou Dalle, Alexandros Spyridonidis, Gesine Bug, Jordi Esteve, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6475–6482.
https://doi.org/10.1158/1078-0432.CCR-20-3134
Published: 15 December 2020
View article titled, Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years
Open the PDF for Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years in another window
Includes: Supplementary data